-  Pre-registration: Patients must have local diagnosis of papillary craniopharyngioma
             and have tissue slides available for submission to central pathology review; central
             pathology review will include immunohistochemistry (IHC) testing for BRAF V600E
             mutation (VE1 clone) and beta-catenin IHC (membranous, non-nuclear pattern) if needed
             to confirm diagnosis of papillary craniopharyngioma

          -  Histologically proven papillary craniopharyngioma as documented by central pathology
             review with positive BRAF V600E mutation by IHC

          -  Measurable disease and/or non-measurable disease

               -  Measurable disease, defined as bidimensionally measurable lesions with clearly
                  defined margins by magnetic resonance imaging (MRI) scans, with a minimum
                  diameter of 10 mm in both dimensions

               -  Progressive disease required in cohort B, defined as an increase in the
                  bidirectional area by 25% within the past 13 months after surgery or radiation;
                  progressive or recurrent disease is not required in cohort A, but is allowed
                  provided it is a new diagnosis and patient has not received prior treatment.

          -  Prior treatment

               -  Cohort A: No prior therapy received other than surgery

               -  Cohort B: Prior radiation therapy required (any type of prior radiation is
                  allowed)

                    -  For patients treated with external beam radiation therapy, interstitial
                       brachytherapy or radiosurgery, an interval of >= 3 months must have elapsed
                       from completion of radiation therapy to registration

                    -  Recovered to Common Terminology Criteria for Adverse Events (CTCAE) grade 1
                       or less toxicity attributed to radiation with exception of alopecia, fatigue

               -  For patients enrolling on Cohort A or Cohort B:

                    -  For patients treated with surgery, an interval of >= 21 days must have
                       elapsed prior to registration

                    -  No prior treatment with BRAF or MEK inhibitors

                    -  Steroid dosing stable for at least 4 days prior to registration

          -  Not pregnant and not nursing; for women of childbearing potential only, a negative
             pregnancy test done =< 7 days prior to registration is required

          -  ECOG performance status =< 2

          -  Comorbid conditions

               -  No evidence of active bleeding, bleeding diathesis, or hemoptysis (>= 1/2
                  teaspoon of red blood) =< 8 weeks prior to registration

               -  No evidence of intracranial hemorrhage =< 4 weeks prior to registration

               -  Patients who have experienced thromboembolic event within 6 months prior to
                  registration must be on stable therapeutic anticoagulation for at least 4 weeks
                  prior to registration

               -  No symptomatic congestive heart failure (New York Heart Association class II,
                  III, or IV) within 6 months prior to registration

               -  No current unstable angina or uncontrolled arrhythmia

               -  No uncontrolled hypertension at time of registration (blood pressure [BP] >
                  150/95 despite antihypertensive therapy)

               -  No known history of prolonged QT syndrome

               -  No known history of ventricular arrhythmia within 6 months of registration

               -  No known history of uveitis or iritis =< 4 weeks prior to registration

               -  No known history of or evidence of retinal pathology that is considered a risk
                  factor for neurosensory retinal detachment, retinal vein occlusion (RVO), or
                  neovascular macular degeneration within 12 months of registration

               -  No known history of chronic lung disease

          -  Concomitant medications

               -  Chronic concomitant treatment with strong CYP3A4 inducers or CYP3A4 inhibitors is
                  not allowed; patients must discontinue the drug at least 14 days prior to study
                  registration

               -  Chronic concomitant treatment with CYP1A2 substrate is not allowed; patients must
                  discontinue the drug at least 14 days prior to study registration

          -  Absolute neutrophil count >= 1500/mm^3

          -  Platelets >= 100,000/mm^3

          -  Creatinine =< 1.5 mg/dL OR creatinine clearance >= 45mL/min

          -  Bilirubin =< 1.5 upper limit of normal (ULN)

          -  Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) =< 2.5 ULN